RAS-targeted therapies for pancreatic cancer
Pancreatic adenocarcinoma (PDAC) is a RAS-driven cancer with poor prognosis. Although tremendous progress has been made in other cancers with the development of targeted therapies and immunotherapy, cytotoxic chemotherapy remains the mainstay of treatment for PDAC. For decades, the therapeutic development of RAS-target...